peficitinib
Selected indexed studies
- Peficitinib: First Global Approval. (Drugs, 2019) [PMID:31093950]
- Efficacy and safety of peficitinib in rheumatoid arthritis. (Mod Rheumatol, 2020) [PMID:32643492]
- Peficitinib improves bone fragility by recovering bone turnover imbalance in arthritic mice. (J Pharmacol Sci, 2022) [PMID:34924117]
_Worker-drafted node — pending editorial review._
Connections
peficitinib is a side effect of
Sources
- Peficitinib: First Global Approval. (2019) pubmed
- Efficacy and safety of peficitinib in rheumatoid arthritis. (2020) pubmed
- Peficitinib improves bone fragility by recovering bone turnover imbalance in arthritic mice. (2022) pubmed
- Peficitinib halts acute kidney injury via JAK/STAT3 and growth factors immunomodulation. (2024) pubmed
- Peficitinib alleviated acute lung injury by blocking glycolysis through JAK3/STAT3 pathway. (2024) pubmed
- JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis. (2019) pubmed
- Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. (2020) pubmed
- Peficitinib hydrobromide to treat rheumatoid arthritis. (2020) pubmed
- JAK inhibitors for rheumatoid arthritis. (2023) pubmed
- Peficitinib suppresses diffuse-type tenosynovial giant cell tumor by targeting TYK2 and JAK/STAT signaling. (2025) pubmed